Detalhe da pesquisa
1.
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.
Breast Cancer Res Treat
; 205(1): 87-95, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38291268
2.
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.
Breast Cancer Res
; 25(1): 145, 2023 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37968696
3.
Bladder-sparing (chemo)radiotherapy in elderly patients with muscle-invasive bladder cancer: a retrospective cohort study.
Acta Oncol
; 61(8): 1019-1025, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35880448
4.
A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design.
Eur J Cancer
; 207: 114159, 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38878446
5.
Comprehensive characterization of circulating tumor cells and cell-free DNA in patients with metastatic melanoma.
Mol Oncol
; 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38790134
6.
Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival.
NPJ Breast Cancer
; 9(1): 61, 2023 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37452019
7.
Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review.
Cancer Treat Rev
; 106: 102384, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35366566
8.
Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients.
Cancers (Basel)
; 14(18)2022 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36139564